MinervaX
minervax.com
Biotechnology
Vaccines
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Minervax raises €47.4m in Series B funding round for GBS shot
Denmark's MinervaX has raised €47.4 million in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials.
Read more
Report
MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late-stage development, global regulatory and operational expertise as MinervaX enters its next phase of growthBuilds on robust Phase II results, paving the way for
Read more
Report
MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late-stage development, global regulatory and operational expertise as MinervaX enters its next phase of growthBuilds on robust Phase II results, paving the way for
Read more
Report
MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late-stage development, global regulatory and operational expertise as MinervaX enters its next phase of growth Builds on robust Phase II results, paving the way for
Read more
Report
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX
/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today...
Read more
Report
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair of MinervaX
Copenhagen, Denmark, November 14, 2024 - MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announced the appointment of Veronica Gambillara Fonck as its new Chai
Read more
Report
MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
MinervaX scaling up supply of novel GBS vaccine, ahead of phase III studies Wacker Biotech to manufacture active vaccine protein ingredients and prepare for commercial supply after regulatory approval Vaccine to address the unmet medical burden of GBS, bo
Read more
Report
MinervaX and Wacker Biotech Announce Manufacturing Collaboration for Prophylactic Vaccine Targeting Group B Streptococcus
Read more
Report
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the financing The financing supports the Company's efforts to commence a Phase III clin
Read more
Report
MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 Copenhagen, Denmark, 27 June 2023 - MinervaX
Read more
Report
Show more news